The GORE® TIGRIS® Vascular Stent delivers the ideal combination for high-flexion performance in the proximal popliteal.
- Conformability that retains the natural shape of the vessel, allowing axial compression while resisting stent elongation
- Flexibility that enables movement in high-flexion anatomy, allowing natural vessel movement
- Long-term fracture resistance with zero reported stent frame fractures at
GORE® TIGRIS® Vascular Stent: Advanced technology engineered for lasting performance.
Giving you the confidence that you are delivering the most durable treatment options to your patients.
- Clinically established helically-wound nitinol frame, leverages the stent technology of the GORE® VIABAHN® Endoprosthesis, provides luminal radial strength
- Fluoropolymer interconnecting structure enables performance in high-flexion anatomies
- CBAS Heparin Surface, also featured in the GORE® PROPATEN® Vascular Graft, is the proven, lasting heparin technology designed to resist thrombus formation*
High-flexion conformability: Optimal combination of straightening force and elongation, allowing the artery to bend and move naturally.3
Long-term fracture resistance: Zero reported stent frame fractures at 12, 24, and 36 months.4
Accuracy with minimal elongation: Average elongation < 0.1% in a U.S. Clinical Study.5
On target, every time: Single-handed, precise delivery — 100% of stents deployed within the nominal length.1
Proven lasting thromboresistance: Improved surface hemocompatibility resulting from heparin availability and bioactivity.*
* CBAS Heparin Surface. W. L. Gore & Associates web site. https://www.goremedical.com/cbas/references. Accessed July 30, 2018.
** Tested as IDEV® SUPERA® Stent
ABBOTT® and SUPERA® are trademarks of Abbott Laboratories.
BD® and LIFESTENT® are trademarks of Becton, Dickinson, and Company.
COOK®, ZILVER®, and PTX® are trademarks of Cook Medical Inc.
- U.S. Food and Drug Administration. Center for Devices and Radiological Health. FDA Summary of Safety and Effectiveness Data. P160004. http://www.accessdata.fda.gov/cdrh_docs/pdf16/P160004B.pdf. Published July 27, 2016. Accessed August 10, 2016.
- Werner M. The Tigris dual component stent (from Gore): advantages and 1-year results in treating SFA-pop occlusive lesions: from the Austrian Registry. Presented at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium); November 13-17, 2018; New York, NY.
- Hoopingarner E. TIGRIS / Viabahn Stent Competitor Testing. Part 2. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2014. [Work plan]. WP106734.
- W. L. Gore & Associates, Inc. Evaluation of the GORE® TIGRIS® Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries. [Final Post-Approval Study Report-Executive
Summary]. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2017. MD165299.
- Laird JR, Zeller T, Loewe C, et al. Novel nitinol stent for lesions up to 24 cm in the superficial femoral artery and proximal popliteal arteries: 24-month results from the TIGRIS Randomized Trial. Journal of Endovascular Therapy
- Supera® Peripheral Stent System [Instructions for Use]. Santa Clara, CA: Abbott Vascular; 2016. EL2100430.
- Biran R. Thromboresistance Evaluation of the GORE® TIGRIS Vascular Stent and Commercial Competitor Stents in an In Vitro Blood Contact Model. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2012. [Work plan]. WP 103833.